Delving into the Latest Updates on HS-10384 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

HS 10384, HS-10384, HS10384

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesOther Diseases

Active Indication

Hot FlashesVasomotor symptom

Inactive Indication-

Originator Organization

Changzhou Humon Pharmaceutical Co., Ltd.

Shanghai Hansoh Biomedical Co. Ltd.

Active Organization

Shanghai Hansoh Biomedical Co. Ltd.Changzhou Humon Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary study objective: To evaluate the effect of food on the pharmacokinetics of HS-10384 after a single oral administration of HS-10384 tablets to healthy female subjects. Secondary study objective: To evaluate the safety of HS-10384 tablets after a single oral administration to healthy female subjects.

Start Date29 Feb 2024

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

[+1]

NCT06122181

/ RecruitingPhase 1

A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HS-10384 in Chinese Postmenopausal Women

A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.

Start Date12 Nov 2023

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

100 Clinical Results associated with HS-10384

Login to view more data

100 Translational Medicine associated with HS-10384

Login to view more data

100 Patents (Medical) associated with HS-10384

Login to view more data

100 Deals associated with HS-10384

Login to view more data